Related Experiment Video

Updated: Apr 26, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

9.9K

Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis

Kangxing Song1, Shuxia Wang, Bihui Huang

  • 1Yale Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; The Cardiology Department, Chinese Peoples' Liberation Army General Hospital, Beijing, China.

Journal of Clinical Hypertension (Greenwich, Conn.)
|July 24, 2014
PubMed

Insights

Cardiotrophin-1 (CT-1) is linked to higher risks of heart failure and hypertension. This meta-analysis confirms elevated CT-1 levels in patients with these conditions, suggesting its potential as a prognostic biomarker.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Discovery
  • Cytokine Research

Background:

  • Cardiotrophin-1 (CT-1), part of the interleukin 6 cytokine superfamily, has been implicated in heart failure and hypertension.
  • Previous studies on plasma CT-1 levels and hypertensive heart disease progression are limited.
  • Understanding the role of CT-1 in hypertension-related cardiac conditions is crucial.

Purpose of the Study:

  • To conduct a meta-analysis assessing the association between plasma CT-1 levels and hypertension, cardiac hypertrophy, and heart failure (HF).
  • To investigate whether CT-1 levels predict the progression of hypertensive heart disease.
  • To evaluate CT-1 as a potential biomarker for prognosis in hypertensive patients.

Main Methods:

  • A meta-analysis of 18 published studies and electronic databases.
  • Data extraction using standardized algorithms and direct investigator contact.
  • Analysis of CT-1 levels in patients with hypertension, cardiac hypertrophy, and heart failure compared to controls.

Main Results:

  • Significantly higher serum CT-1 levels were observed in patients with hypertension (SMD, 0.85), left ventricular hypertrophy (SMD, 0.88), and HF (SMD, 0.66) compared to controls.
  • Subgroup analysis showed the highest CT-1 levels in patients with hypertension-induced hypertrophy and HF.
  • Elevated CT-1 levels were associated with hypertension without left ventricular hypertrophy (SMD, 0.67).

Conclusions:

  • Increased plasma CT-1 levels are significantly associated with heart failure risk in hypertensive patients.
  • CT-1 may serve as a novel and valuable biomarker for predicting prognosis in individuals with hypertension.
  • Further research into CT-1's role in cardiovascular disease progression is warranted.

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

9.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
750
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
849
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K